financetom
Business
financetom
/
Business
/
Science Applications International Lifts Full-Year Earnings Outlook Following Fourth-Quarter Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Science Applications International Lifts Full-Year Earnings Outlook Following Fourth-Quarter Beat
Mar 17, 2025 8:07 AM

10:46 AM EDT, 03/17/2025 (MT Newswires) -- Science Applications International's ( SAIC ) shares rallied Monday as the US government services contractor increased its fiscal 2026 earnings outlook and posted stronger-than-expected results for the fourth quarter.

The company now expects adjusted per-share earnings between $9.10 and $9.30 for the ongoing fiscal year, up from its prior outlook of $8.90 to $9.10. The consensus on FactSet is for $9.06. Adjusted EPS in the previous fiscal year that ended Jan. 31 rose 16% year over year to $9.13.

Revenue is projected to be in the range of $7.60 billion to $7.75 billion, reflecting a higher bottom end than the previous $7.55 billion estimate. Analysts are looking for $7.63 billion. Revenue in fiscal 2025 totaled $7.48 billion versus $7.44 billion in the year prior.

"Subsequent to quarter close, we received a $1.8 billion award for our largest recompete win in recent years, the System Software Lifecycle Engineering program," Chief Executive Toni Townes-Whitley said in a statement. "This important win along with a backlog of submitted bids valued at approximately $20 billion reflect the momentum we are building inside the company."

The company's shares soared 11% in Monday trade.

Adjusted EPS in the fiscal fourth quarter rose to $2.57 from $1.43 a year earlier, ahead of the $2.09 consensus on FactSet. Revenue in the quarter increased 6% year over year to $1.84 billion, exceeding the $1.82 billion estimate projected by analysts. Sales increased amid volume growth due to new and existing contracts, partially offset by contract completions.

Net bookings for the quarter totaled $1.3 billion, resulting in a book-to-bill ratio of about 0.7.

The company's backlog at the end of fiscal 2025 was about $21.86 billion, of which $3.44 billion was funded.

Price: 115.40, Change: +10.97, Percent Change: +10.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved